8-K: Recursion Pharmaceuticals and Exscientia Amend Merger Agreement, Adding Board Seats

Recursion Pharmaceuticals and Exscientia have amended their merger agreement to include the appointment of two Exscientia board members to Recursion's board, with one additional board member to be mutually agreed upon.

Summary

• Recursion Pharmaceuticals and Exscientia have amended their transaction agreement, originally dated August 8, 2024, regarding Recursion's acquisition of Exscientia.
• The amendment, dated November 5, 2024, stipulates that Recursion will appoint one member of Exscientia's board to its own board effective at the time of the merger.
• Recursion will also appoint an additional board member if mutually agreed upon by both companies before the merger is complete.
• The original agreement stated that each Exscientia share would be exchanged for 0.7729 shares of Recursion Class A Common Stock.
• The supplemental disclosures provide additional background on the transaction, including initial discussions in 2022 and the formation of a Recursion Transaction Committee.
• Financial analysis by Allen & Company estimated Exscientia's enterprise value between $124 million and $719 million, and transaction values between $458 million and $1.011 billion.
• Discounted cash flow analysis by Allen & Company used a discount rate range of 13.25% to 15.75% and a perpetuity growth rate range of 2.75% to 3.25%.
• Centerview's discounted cash flow analysis for Exscientia resulted in an implied equity value range of $3.90 to $6.60 per share.
• Exscientia's risk-adjusted forecasts project net revenue to reach $659 million by 2049, while Recursion's forecasts project net revenue to reach $976 million by 2049.
• Litigation has been filed against Recursion and its board members alleging misrepresentation and concealment related to the merger.

Sentiment

Score: 6

Explanation: The document is neutral to slightly positive. While it details a significant merger and provides financial analysis, it also acknowledges risks and litigation. The amendment to the agreement is a positive step, but the overall sentiment is tempered by the uncertainties and challenges ahead.

Positives

• The amendment to the merger agreement ensures representation from Exscientia on Recursion's board.
• The inclusion of an additional board member, if mutually agreed, could bring further expertise and balance.
• The transaction is progressing with supplemental disclosures providing more transparency.
• The financial analysis provides a range of valuations for Exscientia, aiding in understanding the deal's value.

Negatives

• Litigation has been filed against Recursion and its board, which could cause delays or complications.
• The financial forecasts for both companies show significant losses in the near term before profitability is achieved.
• The merger process has involved significant legal and financial analysis, indicating complexity and potential risks.

Risks

• The merger could be terminated if certain conditions are not met, including shareholder approvals and regulatory clearances.
• There is a risk of disruption to both companies' operations during the merger process.
• The integration of Exscientia's business with Recursion's could be challenging.
• The outcome of the litigation against Recursion is uncertain and could impact the merger.
• The combined company's future performance is subject to various market and business risks.
• The financial forecasts are based on assumptions that may not materialize, impacting future revenue and profitability.

Future Outlook

The document includes forward-looking statements regarding the transaction and the future business and financial performance of both companies, which are subject to various risks and uncertainties. The combined company is expected to achieve profitability in the future, but the timing and extent of this are uncertain.

Management Comments

• Dr. Gibson and Dr. Hopkins discussed a potential merger of equals transaction.
• The Recursion Board agreed that Dr. Gibson would continue to serve as chief executive officer of the combined company.
• Recursion management provided financial forecasts and estimates to Allen & Company.
• Exscientia management provided financial forecasts and estimates to Centerview.

Industry Context

This merger is occurring in the biopharma industry, where companies are increasingly seeking strategic combinations to enhance their drug discovery capabilities and market presence. The transaction reflects a trend of consolidation and collaboration in the sector to leverage technology and resources.

Comparison to Industry Standards

• The document references selected public companies and precedent transactions for valuation purposes, but notes that no company or transaction is directly comparable to Recursion or Exscientia.
• The financial analysis includes a range of estimated enterprise and transaction values, which are common in merger evaluations.
• The use of discounted cash flow analysis is a standard practice in valuing biotech companies with long-term development pipelines.
• The document mentions Wall Street research analyst price targets for both companies, which are typical benchmarks used in financial analysis.
• The projected revenue and profitability timelines are consistent with the long development cycles typical in the biopharmaceutical industry.

Management Changes

Legal Proceedings

• Two lawsuits have been filed against Recursion and its board members alleging misrepresentation and concealment related to the merger.
• The lawsuits seek to enjoin the merger and claim damages.

Stakeholder Impact

• Shareholders of both Recursion and Exscientia will be impacted by the merger, with Exscientia shareholders receiving Recursion stock.
• Employees of both companies may experience changes due to the integration process.
• Customers and partners of both companies may see changes in the combined company's offerings and operations.
• Creditors of both companies will be impacted by the merger, with the combined company assuming liabilities.

Next Steps

• Recursion and Exscientia need to obtain shareholder approvals for the merger.
• The High Court of Justice of England and Wales needs to sanction the Scheme of Arrangement.
• Regulatory approvals need to be obtained.
• The companies need to integrate their businesses after the merger is complete.
• Recursion will appoint two members of the Exscientia board to its board.
• Recursion will appoint an additional board member if mutually agreed upon.

Key Dates

Keywords

merger, acquisition, transaction agreement, board of directors, share exchange, financial analysis, discounted cash flow, litigation, biopharma, Exscientia, Recursion Pharmaceuticals